VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

• Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo
  

BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.

“We look forward to sharing our preclinical and Phase 1b data for VYN201 with researchers and clinicians at the upcoming SID Annual Meeting,” said Iain Stuart, Ph.D., Chief Scientific Officer of VYNE. “Our data support the advancement of VYN201 as a differentiated therapy for the potential treatment of nonsegmental vitiligo.”

Presentation Details:

1.	Title:	Preclinical studies: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
	Final ID Number:	LB1055
	Session:	Select E-Poster Discussions (Session 1): Late Breaking Abstracts
	Session Category:	Translational Studies and Early Preclinical to Clinical
	Presenter:	Dr. Iain Stuart
	Session Date/Time:	Thursday, May 16, 2024, 5:00-6:30 p.m. CDT
	Location:	Trinity Exhibit Hall, Stage 5

2.	Title:	Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
	Final ID Number:	LB1056
	Session:	Concurrent Mini-Symposium 18: Late Breaking Abstracts
	Session Category:	Translational Studies and Early Preclinical to Clinical
	Presenter:	Dr. Iain Stuart
	Session Date/Time:	Saturday, May 18, 2024, 10:00 a.m.-12:30 p.m. CDT
	Location:	Cortez C/D

About Vitiligo